NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.45

+0.01 (+2.27%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.44
▼
$0.49
50-Day Range: $0.37
▼
$0.51
52-Week Range: $0.36
▼
$1.89

Volume: 54,289 shs
Average Volume: 160,845 shs
Market Capitalization: $39.84 million

P/E Ratio: 11.25
Dividend Yield: N/A
Price Target: $4.00

Lipocine MarketRank™ Forecast

Analyst Rating: N/A
0.00 Rating Score
Upside/Downside: 788.7% Upside
$4.00 Price Target
Short Interest: Healthy
1.81% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$51,217 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.13) to ($0.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

853rd out of 1,043 stocks

Pharmaceutical Preparations Industry

414th out of 510 stocks

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Lipocine has a forecasted upside of 788.7% from its current price of $0.45.
Amount of Analyst Coverage
Lipocine has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.81% of the float of Lipocine has been sold short.
Short Interest Ratio / Days to Cover
Lipocine has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Lipocine has recently decreased by 3.11%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Lipocine does not currently pay a dividend.
Dividend Growth
Lipocine does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LPCN.

2.0

News and Social Media Coverage

News Sentiment
Lipocine has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Lipocine this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for LPCN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,217.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Lipocine is held by insiders.
Percentage Held by Institutions
Only 13.45% of the stock of Lipocine is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Lipocine are expected to grow in the coming year, from ($0.13) to ($0.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lipocine is 11.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.01.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lipocine is 11.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.67.
Price to Book Value per Share Ratio
Lipocine has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

November 29, 2022 | americanbankingnews.com

Lipocine Inc. (NASDAQ:LPCN) Director Spyros Papapetropoulos Buys 21,739 Shares

November 29, 2022 | americanbankingnews.com

Lipocine (NASDAQ:LPCN) Receives New Coverage from Analysts at StockNews.com

December 1, 2022 | Investing Trends (Ad)

Without Graphite, There Would Be ZERO EV Batteries!

Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.

November 21, 2022 | americanbankingnews.com

Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

November 9, 2022 | finance.yahoo.com

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

November 3, 2022 | finance.yahoo.com

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

October 11, 2022 | finance.yahoo.com

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo Finance

October 11, 2022 | finance.yahoo.com

Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference

December 1, 2022 | Investing Trends (Ad)

A $226B Copper Spending Jackpot

On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.

September 27, 2022 | finance.yahoo.com

Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

September 27, 2022 | seekingalpha.com

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% - Seeking Alpha

September 26, 2022 | finance.yahoo.com

Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets

September 26, 2022 | finance.yahoo.com

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

September 23, 2022 | finance.yahoo.com

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Yahoo Finance

September 22, 2022 | finance.yahoo.com

Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

September 16, 2022 | finance.yahoo.com

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo Finance

September 15, 2022 | nasdaq.com

Lipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - Nasdaq

September 15, 2022 | benzinga.com

Lipocine (NASDAQ:LPCN) – Lipocine Announces Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depressi - Benzinga

September 15, 2022 | finance.yahoo.com

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

August 10, 2022 | finance.yahoo.com

LPCN: TLANDO Launched

August 9, 2022 | finance.yahoo.com

Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

August 8, 2022 | apnews.com

Lipocine: Q2 Earnings Snapshot

August 8, 2022 | benzinga.com

Recap: Lipocine Q2 Earnings - Benzinga

August 8, 2022 | streetinsider.com

Form 10-Q Lipocine Inc. For: Jun 30 - StreetInsider.com

August 8, 2022 | seekingalpha.com

Lipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M (NASDAQ:LPCN) - Seeking Alpha

August 8, 2022 | streetinsider.com

Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com

August 8, 2022 | finance.yahoo.com

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings: 11/10/2021
Today: 12/01/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/08/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LPCN
CUSIP: N/A
CIK: 1535955
Web: www.lipocine.com
Phone: (801) 994-7383
Fax: 801-994-7388
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +788.7%
Consensus Rating: N/A
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.04
Trailing P/E Ratio: 11.25
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-630,000.00
Net Margins: N/A
Pretax Margin: 24.69%
Return on Equity: 9.90%
Return on Assets: 9.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.90
Quick Ratio: 23.90

Sales & Book Value

Annual Sales: $16.14 million
Price / Sales: 2.47
Cash Flow: $0.05 per share
Price / Cash Flow: 9.95
Book Value: $0.43 per share
Price / Book: 1.05

Miscellaneous

Outstanding Shares: 88,510,000
Free Float: 83,908,000
Market Cap: $39.84 million
Optionable: Optionable
Beta: 0.55

Key Executives

Dr. Mahesh V. Patel Ph.D. (Age 65)
Co-Founder, Interim Principal Financial Officer, Chairman, Pres & CEO
Comp: $681.52k

Mr. Morgan R. Brown CPA (Age 54)
CPA, M.B.A., MBA, Corp. Sec.
Comp: $472.45k

Mr. Nachiappan Chidambaram Ph.D. (Age 53)
VP of Product Devel.
Comp: $323.22k

Mr. Logan Morse (Age 52)
VP of Sales, Marketing & Operations

Ms. Krista Fogarty (Age 54)
Principal Accounting Officer & Corp. Controller

Dr. Anthony DelConte M.D. (Age 64)
M. D., Chief Medical Director

Dr. George G. Nomikos M.D.
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?: 0 analysts have issued twelve-month price targets for Lipocine's shares. Their LPCN share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 788.7% from the stock's current price.
View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts.
How have LPCN shares performed in 2022?: Lipocine's stock was trading at $0.9911 at the beginning of the year. Since then, LPCN stock has decreased by 54.6% and is now trading at $0.4501.
View the best growth stocks for 2022 here.
When is Lipocine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our LPCN earnings forecast.
How were Lipocine's earnings last quarter?: Lipocine Inc. (NASDAQ:LPCN) released its quarterly earnings data on Wednesday, November, 10th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. The specialty pharmaceutical company had revenue of $0.06 million for the quarter.

What other stocks do shareholders of Lipocine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).
What is Lipocine's stock symbol?: Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
Who are Lipocine's major shareholders?: Lipocine's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.64%), Two Sigma Investments LP (0.37%), Two Sigma Advisers LP (0.24%), Renaissance Technologies LLC (0.23%), Mercer Global Advisors Inc. ADV (0.18%) and Virtu Financial LLC (0.11%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown and Spyros Papapetropoulos.
View institutional ownership trends.
How do I buy shares of Lipocine?: Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lipocine's stock price today?: One share of LPCN stock can currently be purchased for approximately $0.45.
How much money does Lipocine make?: Lipocine (NASDAQ:LPCN) has a market capitalization of $39.84 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.
How can I contact Lipocine?: Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial